TY - JOUR
T1 - Integrative multi-omics characterization of hepatocellular carcinoma in Hispanic patients
AU - Das, Debodipta
AU - Wang, Xiaojing
AU - Chiu, Yu Chiao
AU - Bouamar, Hakim
AU - Sharkey, Francis E.
AU - Lopera, Jorge E.
AU - Lai, Zhao
AU - Weintraub, Susan T.
AU - Han, Xianlin
AU - Zou, Yi
AU - Chen, Hung I.H.
AU - Zeballos Torrez, Carla R.
AU - Gu, Xiang
AU - Cserhati, Matyas
AU - Michalek, Joel E.
AU - Halff, Glenn A.
AU - Chen, Yidong
AU - Zheng, Siyuan
AU - Cigarroa, Francisco G.
AU - Sun, Lu Zhe
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].
PY - 2024/12/1
Y1 - 2024/12/1
N2 - BACKGROUND: The incidence and mortality rates of hepatocellular carcinoma among Hispanic individuals in the United States are much higher than in non-Hispanic White people. We conducted multi-omics analyses to elucidate molecular alterations in hepatocellular carcinoma among Hispanic patients. METHODS: Paired tumor and adjacent nontumor samples were collected from 31 Hispanic hepatocellular carcinomas in South Texas for genomic, transcriptomic, proteomic, and metabolomic profiling. Serum lipids were profiled in 40 Hispanic and non-Hispanic patients with or without clinically diagnosed hepatocellular carcinoma. RESULTS: Exome sequencing revealed high mutation frequencies of AXIN2 and CTNNB1 in South Texas Hispanic hepatocellular carcinoma patients, suggesting a predominant activation of the Wnt/β-catenin pathway. TERT promoter mutations were also statistically significantly more frequent in the Hispanic cohort (Fisher exact test, P < .05). Cell cycles and liver function were positively and negatively enriched, respectively, with gene set enrichment analysis. Gene sets representing specific liver metabolic pathways were associated with dysregulation of corresponding metabolites. Negative enrichment of liver adipogenesis and lipid metabolism corroborated with a significant reduction in most lipids in serum samples of hepatocellular carcinoma patients (paired t test, P < .0001). Two hepatocellular carcinoma subtypes from our Hispanic cohort were identified and validated with the Cancer Genome Atlas liver cancer cohort. Patients with better overall survival showed higher activity of immune and angiogenesis signatures and lower activity of liver function-related gene signatures. They also had higher levels of immune checkpoint and immune exhaustion markers. CONCLUSIONS: Our study revealed specific molecular features of Hispanic hepatocellular carcinoma and potential biomarkers for therapeutic management. It provides a unique resource for studying Hispanic hepatocellular carcinoma.
AB - BACKGROUND: The incidence and mortality rates of hepatocellular carcinoma among Hispanic individuals in the United States are much higher than in non-Hispanic White people. We conducted multi-omics analyses to elucidate molecular alterations in hepatocellular carcinoma among Hispanic patients. METHODS: Paired tumor and adjacent nontumor samples were collected from 31 Hispanic hepatocellular carcinomas in South Texas for genomic, transcriptomic, proteomic, and metabolomic profiling. Serum lipids were profiled in 40 Hispanic and non-Hispanic patients with or without clinically diagnosed hepatocellular carcinoma. RESULTS: Exome sequencing revealed high mutation frequencies of AXIN2 and CTNNB1 in South Texas Hispanic hepatocellular carcinoma patients, suggesting a predominant activation of the Wnt/β-catenin pathway. TERT promoter mutations were also statistically significantly more frequent in the Hispanic cohort (Fisher exact test, P < .05). Cell cycles and liver function were positively and negatively enriched, respectively, with gene set enrichment analysis. Gene sets representing specific liver metabolic pathways were associated with dysregulation of corresponding metabolites. Negative enrichment of liver adipogenesis and lipid metabolism corroborated with a significant reduction in most lipids in serum samples of hepatocellular carcinoma patients (paired t test, P < .0001). Two hepatocellular carcinoma subtypes from our Hispanic cohort were identified and validated with the Cancer Genome Atlas liver cancer cohort. Patients with better overall survival showed higher activity of immune and angiogenesis signatures and lower activity of liver function-related gene signatures. They also had higher levels of immune checkpoint and immune exhaustion markers. CONCLUSIONS: Our study revealed specific molecular features of Hispanic hepatocellular carcinoma and potential biomarkers for therapeutic management. It provides a unique resource for studying Hispanic hepatocellular carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85212457155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85212457155&partnerID=8YFLogxK
U2 - 10.1093/jnci/djae207
DO - 10.1093/jnci/djae207
M3 - Article
C2 - 39189979
AN - SCOPUS:85212457155
SN - 0027-8874
VL - 116
SP - 1961
EP - 1978
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 12
ER -